Tag Archives | ADC antibody-drug conjugates

Biotech Mid-Cap Momentum Leaders and Laggards…Update…gene editing

click Update-1 Gene Editing stocks are hit hard by a STAT Report that edited cells may cause cancer. Here is a later summary from STAT. As of 2:45 PDT trading; CRSP down 12% at $60,  EDIT down 7.8% at $36.14. NTLA down 9.9% at $24.5. The report was published in Nature Medicine. After the close biotech […]

Continue Reading 0

ASCO 2018 Biotech Rally Part 2 : Traders Take Profits on Nice Gains…Updates

order gabapentin online ASCO 2018 Rally Part 2: Traders Take Profits on Nice Gains Biotech Indices and ETFs Show Gains YTD: FBIOX up 8% YTD,  IBB up 3.13%, XBI up 9.34% The ASCO 2018 biotech rally was almost according to the script-nice gains leading up to the meeting followed by momentum easing from profit taking and digestion of news. […]

Continue Reading 0

Biotechs Survive 2018 Bottom and Catch a Rally Today…Update 5/9

see url Update 5/8/18 Biotechs Rally Above Near Term Support (XBI) at SMA 20 XBI up 1.96% to $89.80. IBB up 1.35% to $103.79; twelve month quadruple bottom is near $100 level. Small and mid caps should outperform because of news and M&A potential. Large caps: Celgene (CELG) down 20.66% over 12 month lows at $82.80. Large caps: Abbvie(ABBV) […]

Continue Reading 0

Biotechs Stalled and Get No Help From Monday’s Market Moves…Updates

Updates: 4/19/18 GWPH hits $143 new high,  then sold off holding $134 level, after big move from $105 on cannabis drug for severe epilepsy FDA Advisory go ahead. Biotechs broadly in the red except CRSP up 6.4% and NVCR up 5%. AstraZeneca (AZN) gained US approval for 1st line use of lung cancer drug. Novartis (NVS) shares […]

Continue Reading 0

Weak NASDAQ Leaves Biotech Stocks Stalled…Update-1

Update-1 …March 18- Market jittery on potential global trade war, rising interest rate concerns and political risk. Also Sales to U.S. retailers fell 0.1% in February a 3 month slide. Biotechs are in a risk-off mode with a weak tape. Dow down 0.47%, NASDAQ down 0.2%, IBB down 0.98%, XBI down 1.56% Biotechs stocks were red across […]

Continue Reading 0

Biotechs Buffeted by Macro News But Should Continue to Outperform…Update-1

Update-1 March 10… Broad Rally Continues Through The Week QQQ Up 4.3% IBB up 4.3% XBI up 4.8% Gene Editing Stocks Surge Biotech stocks soared along with the market as fear about interest rates, tariffs and global politics subsided helped considerably by economic sentiment and jobs. Moreover the employment report showed wage gains revised downward […]

Continue Reading 0

Rayno BioBeat 2018 #2: Biotech Deal Sparks Rally…Update-1

Update-1 …2/17/18 Good Week for Biotech: FBT up 6.29%, IBB up 4.44%, XBI up 6.26% Biotech stocks continued their strong recovery from the big sell-off in the prior week but about 3% under 2018 highs. Biotech ETFs tracked the QQQ up 5.68% for the week but biotech stocks are leaders YTD beating the S&P 500. […]

Continue Reading 0

How Bad Was The Biotech Selloff Last Week?…Updates-2/6

Updates-2… 2/6/18 Biotechs Down With Overall Market Over 5 Days  Closing Prices as of 2/6/18 XBI up 3% at $91.05 down 5.34% over 5 days IBB up 2% at $109.36 down 7.35% over 5 days QQQ up 2.65% at $162.31 down 5.04% over 5 days By now you have read about all the possible reasons […]

Continue Reading 0

What’s Next After Profit Taking Hits Biotech and Drug Stocks?

Profit Taking Hits Biotech Stocks Disruption Coming to Healthcare? Another Round of Sector Rotation? The biotech sector hit a wall after breaking through to new highs last week. The major news that sparked profit taking on Tuesday was that Amazon, Berkshire Hathaway and J.P.Morgan formed a consortium to address rising healthcare costs by trying to […]

Continue Reading 0

Biotech is Hot Sparked By Biotech M&A Deals for Juno and Bioverativ…Update-1

Update-1 Jan 23, 2018… Biotech Breakout Rally Continues The biotech rally cruised on to the second day with the smaller cap, equal weighted XBI moving up 2% to $95.82 a 12 month high. The large cap weighted IBB followed up 1.12% to $116.81 also a 12 month high. The media especially CNBC trucked right along […]

Continue Reading 0